Skip to main content
Edinburgh BioQuarter
BioCentury, the Bernstein Report on BioBusiness
As published for the week of Monday, May 20, 2013


  • Cover Story: Strategy: Paying for Procysbi

    How Raptor is making its case for ultra-Orphan drug Procysbi's $250,000 price

    By Tim Fulmer
    Senior Writer

    Raptor Pharmaceutical Corp. will launch an ultra-Orphan drug this quarter that it has shown to be non-inferior to a cheaper alternative. The company has yet to get any payers on board, but believes it can win them over based on the drug's ability to improve compliance and quality of life for patients with nephropathic cystinosis.

    Raptor has set the U.S. list price of Procysbi (RP103) at $250,000 annually. The immediate-release formulation of the drug, Cystagon cysteamine, is marketed by Mylan Inc. for about $10,000 per year.

    Full Article

Money Raised in 2013

Last week, the biotech industry raised $1,108 million, bringing to $9.6 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 billion in debt, $6.3 billion in follow-ons, $2.8 billion in PIPEs and other equity, $1.1 billion in IPOs, and $6.2 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial
Keck Graduate Institute Johnson & Johnson

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

BioCentury This Week TV Need custom ComputerVision Software?